In China, Rare Dissent Over a Program to Save on Drug Costs
Top doctors raised concerns about domestically made drugs, saying Beijing’s effort to lower costs is sacrificing quality.
Cancer Therapy Advisor2d
Camrelizumab and Rivoceranib Improve Upon TACE in Unresectable HCC
Adding camrelizumab and rivoceranib to TACE improved PFS in patients with unresectable HCC in a phase 2 trial.
中国日报网2d
Nation issues new anti-monopoly guidelines for pharma sector
In an effort to safeguard fair market competition and protect consumer interests, the State Council's anti-monopoly ...
中国日报网3d
Judicial accuracy spotlighted as court revises 'Breaking Bad' drug case rulings
A Chinese court's decision to revise the ruling in a drug case involving a former associate chemistry professor — dubbed the "Chinese version of Breaking Bad" — reflects the country's commitment to ...
BioWorld5d
More China ADCs: Arrivent gets GI cancer drug in $1.2B Lepu deal
A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide ...